Since Xp11.2 tRCC has been formally described as a distinct clinicopathologic entity in 2001, there has been a lot of research attention given to the function of TFE3 fusion proteins [25–27]. The gene discussed is TFE3; the disease is renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions.